ATAI Valuation

ATAI Life Sciences NV

Add to Watchlist

Advanced Chart

3.570

-0.17(-4.545%)1D

Overview
Forecast
Valuation
Earnings

ATAI Relative Valuation

ATAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATAI is overvalued; if below, it's undervalued.

Historical Valuation

ATAI Life Sciences NV (ATAI) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3993.96 is considered Overvalued compared with the five-year average of -4.60. The fair price of ATAI Life Sciences NV (ATAI) is between 0.56 to 1.57 according to relative valuation methord. Compared to the current price of 3.74 USD , ATAI Life Sciences NV is Overvalued By 137.46%.

Relative Value

Fair Zone

0.56-1.57

Current Price：3.74

137.46%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.91

P/B

Median3y

1.54

Median5y

2.20

-9.56

FCF Yield

Median3y

-30.61

Median5y

-23.91

Competitors Valuation Multiple

The average P/S ratio for ATAI's competitors is 733.69, providing a benchmark for relative valuation. ATAI Life Sciences NV Corp (ATAI) exhibits a P/S ratio of 4389.96, which is 498.34% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATAI.O

ATAI Life Sciences NV

4389.96

Average P/S: 733.69

757.35M